Sarah Hein, March Biosciences CEO
October 23, 2024 08:00 AM EDTUpdated 12:13 PM
Financing
Startups
Cell/Gene Tx

Hous­ton start­up March Bio­sciences rais­es $28M to get CAR-T in­to Phase 2

Kyle LaHucik

Senior Reporter

A nim­ble Hous­ton start­up has raised a con­cise $28.4 mil­lion Se­ries A to start a mid-stage tri­al.

The com­pa­ny, named March Bio­sciences, will en­ter Phase …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times